Pomalidomide plus Bortezomib plus Low-Dose Dexamethasone Vs Bortezomib plus Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimismm Trial

著录项

• 来源
  《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共5页
• 作者

  Dimopoulos Meletios A.; Weisel Katja; Moreau Philippe; Anderson Larry; White Darrell J.; San-Miguel Jesus F.; Sonneveld Pieter; Engelhardt Monika; Jenner Matthew W.; Corso Alessandro; Duerig Jan; Pavic Michel; Salomo Morten; Yu Xin; Tuong Vi Nguyen; Bensmaine Amine; Peluso Teresa; Zaki Mohamed; Richardson Paul;

  展开▼
• 作者单位

  Univ Athens Athens Greece;

  Univ Hosp Tuebingen Dept Hematol Oncol &

  Immunol Tubingen Germany;

  Univ Hosp Hotel Dieu Nantes France;

  UT Southwestern Med Ctr Dallas TX USA;

  Dalhousie Univ Halifax NS Canada;

  Clin Univ Navarra Pamplona Spain;

  Erasmus MC Canc Inst Dept Hematol Rotterdam Netherlands;

  Univ Klinikum Freiburg Freiburg Germany;

  Southampton Gen Hosp Southampton Hants England;

  Univ Pavia Policlin San Matteo Pavia Italy;

  Univ Hosp Essen Essen Germany;

  CHUS CRCELB Hop Fleurimont Sherbrooke PQ Canada;

  Copenhagen Univ Hosp Rigshosp Copenhagen Denmark;

  Celgene Corp Summit NJ USA;

  Celgene Corp Summit NJ USA;

  Celgene Corp Summit NJ USA;

  Celgene Corp Summit NJ USA;

  Celgene Corp Summit NJ USA;

  Dana Farber Canc Inst Jerome Lipper Multiple Myeloma Ctr Boston MA 02115 USA;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 血液及淋巴系疾病;
• 关键词